Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q1 FY27 Earnings Presentation
32 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, Aug 12, 2026
Slide 1: Exchange filing cover letter for Q1 FY27 investor presentation
12th August 2026 IOLCP/CGC/2026 National Stock Exchange of India Ltd. BSE Limited, Exchange Plaza, Plot no. C/1, G Block, Pheroze Jeejeebhoy Tower, Bandra-Kurla Complex, Bandra (E), Dalal Street, Mumbai- 400 001 Mumbai - 400 051 Security Code: 524164 Security Symbol: IOLCP Subject: Investor Presenta
Slide 2: IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q1FY27
IOL Chemicals and Pharmaceuticals Limited Investor Presentation Q1FY27
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by IOL Chemicals and Pharmaceuticals Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subsc
Slide 4: Q1 FY27 Performance
IOL Q1 FY27 Performance
Slide 5: Q1 FY27 Standalone Performance Highlights
Q1 FY27 Standalone Performance Highlights Q1 FY27 ₹ 756.3 Cr ₹ 64.5 Cr ₹ 111.7 Cr Revenue from Operations PAT EBITDA 37.1% YoY 60.7% YoY 89.9% YoY EBITDA Margin 14.6% PAT Margin 8.4% FY26 ₹ 2,319.1 Cr ₹ 290.4 Cr ₹ 137.7 Cr Revenue from Operations EBITDA PAT 11.5% YoY 29.3% YoY 36.4% YoY EBITDA Margi
Slide 6: Q1 FY27 Standalone Performance Highlights
Q1 FY27 Standalone Performance Highlights Pharmaceuticals Chemicals (Net of intersegment) Geographical Break-up (In ₹ Cr) (In ₹ Cr) 1396.3 469.5 922.8 286.8 29% 866.9 1212.3 244.9 374.5 222.4 329.3 71% 172.3 62.2 68.8 126.3 40.1 12.8 17.3 15.4 30.2 5.9 FY25 FY26 Q1 FY26 Q4 FY26 Q1 FY27 FY25 FY26 Q1
Slide 7: Standalone Profit & Loss Statement – Q1 FY27
Standalone Profit & Loss Statement – Q1 FY27 Particulars (in INR Cr.) Q1 FY27 Q1 FY26 Y-o-Y Q4 FY26 Q-o-Q FY26 Revenue from Operations 756.3 551.7 37.1% 619.5 22.1% 2319.1 Other Income 8.2 7.4 1.7 21.3 Total Revenue 764.4 559.1 36.7% 621.2 23.1% 2340.3 Cost of Materials Consumed 506.8 376.6 401.7 15
Slide 8: At a Glance
At a Glance
Slide 9: Our Journey- A Story of Resilience and Progress
Our Journey- A Story of Resilience and Progress 1986-91 1996-99 2000-07 2009-13 2015-16 2017-18 2019 - 20 2021-22 2023 2024 2025 2026 • 1986: • 2000 – Production of • 2015 - Received US • 2019 - Commissioned • Increased • Commissioned new Incorporation of Ibuprofen FDA EIR for Ibuprofen Unit 06 (Ded
Slide 10: Business Overview
Business Overview Team size of 3000+ employees Customer base across 80 countries Diversified API Company with Global Fully backward integrated Ibuprofen Leadership Supported by Paracetamol manufacturing facility Backward Integrated Manufacturing with capacity of 10,800 MTPA Platform Among the top gl
Slide 11: Segment Overview- Pharmaceuticals
Segment Overview- Pharmaceuticals Diversified API platform with 30,726 MTPA capacity Expanding non-Ibuprofen API segment with a diversified A fully backward-integrated and automated facility and backward integration across key products. portfolio across multiple therapeutic areas. for manufacturing
Slide 12: Driving Growth Through High-Value APIs
Driving Growth Through High-Value APIs Expanding the non-Ibuprofen Business Installed Capacity Regulatory Filings* Therapeutic Area USDMF, CEP & ANVISA GMP Metformin Hydrochloride 7200 MTPA Anti-Diabetic Approved, China DMF Active USDMF, CEP & ANVISA GMP 60% Fenofibrate 276 MTPA Anti-Cholesterol 59%
Slide 13: Segment Overview- Specialty Chemicals
Segment Overview- Specialty Chemicals Manufacturing Acetic Asia’s first continuous dual REACH-certified for Ethyl Among the largest global Ethyl Acetate Anhydride with capacity of technology plant for MCA Acetate & Acetic Anhydride, manufacturers of Iso Butyl manufacturing capacity of 32,000 MTPA -
Slide 14: State-of-the-Art Facilities
State-of-the-Art Facilities Manufacturing Footprint 18 Manufacturing across API and Plants Specialty Chemicals across API and Specialty Chemicals Integrated. Efficient. Scalable Capacity • Dedicated and multiproduct blocks involved in manufacturing of APIs 2,13,126 MTPA Total Installed Capacity • AP
Slide 15: Innovation & R&D Excellence
Innovation & R&D Excellence 3 21 14 80+ 26 Cr. Patents CEPs with EDQM DMFs with USFDA Countries served R&D Investment during FY26 A 120-member highly skilled team, Working on generic molecules with latest DSIR approved facility for research & including 50+ scientists, driving equipment & techniques
Slide 16: Certifications & Accreditations
Certifications & Accreditations DMF Registration From ANVISA, Brazil CDE of NMPA, China USFDA Approved Facility EUGMP Certification EDQM Certificate of Suitability MFDS Korea GMP Certificate by Russian Kosher Certified WHOGMP (COPP) Certified Written confirmation from CDSCO REACH Certificate Halal C
Slide 17: ESG & Leadership
IOL - - ESG & Leadership ( '
Slide 18: Growth Aligned with Responsibility
Growth Aligned with Responsibility ECOVADIS Gold Medal Recipient ranking among top 5% of companies assessed globally for ESG performance • Reduced combined Scope 1, 2 and 3 GHG emission intensity by 14.4% in FY25–26 • Operate a 100% Zero Liquid Discharge (ZLD) facility Environment • Installed 1,187
Slide 19: Governance Framework
Governance Framework Board Composition 8 10 years Average tenure of Board Independent Director Chairman of the Board Total Independent Directors (4) Managing Director (1) 50% 96% Joint Managing Director (1) Independent Board of Average attendance Executive Director (1) Director Director (works) (1)
Slide 20: Strong Leadership Team
Strong Leadership Team Varinder Gupta | (Managing Director) Mr. Varinder Gupta is an esteemed industrialist with over 38 years of extensive experience in the chemical and pharmaceutical industry. His strategic vision and comprehensive oversight have driven innovation and excellence within the organi
Slide 21: Diverse Board Expertise
Diverse Board Expertise Rajender Mohan Malla Sharad Tyagi Harpal Singh Ms Rajni Jha (Chairman and Independent Director) (Independent Director) (Independent Director) (Independent Director) Mr. Rajender Mohan Malla is a Mr. Sharad Tyagi, with a degree in Mr. Harpal Singh, a Chartered Engineer Ms. Raj
Slide 22: Creating Impact Across Communities
Creating Impact Across Communities ₹ 4.65 Cr Total CSR investment during FY26 | ~5.5 lakh Lives impacted • ₹2.79 crore invested in healthcare initiatives • ₹1.40 crore invested in social upliftment initiatives • 47 lakh invested in education initiatives • New patient ward and care centre supported a
Slide 23: Industry Overview
Industry Overview
Slide 24: API Industry
API Industry Global API Market Size (In USD Bn) Indian API Market Size (In USD Bn) 4.22% 376.2 41.6 Generic APIs lead at 58.4%, 7.78% India is the 3rd largest North America holds over 38% of expected to grow at ~8.2% API producer globally, the API market in 2025. 256.4 CAGR till 2034, underpinned su
Slide 25: Specialty Chemicals Industry
Specialty Chemicals Industry Global Spec. Chem Market Size Indian Spec. Chem Market Size Region wise Spec. Chem Market Size Growth (FY25-29) (In USD Bn) (In USD Bn) 11% 3.13% 3.65% 1078.8 93.4 805.5 67.0 6% 5% 4% 3% 2025 2034 2025 2034 Japan South Korea China Taiwan India Growth shown is CAGR during
Slide 26: Historical Performance
Historical Performance
Slide 27: Historical Standalone Performance
Historical Standalone Performance Revenues EBITDA & EBITDA % Cash Profit After Tax 11.2% 12.1% 10.7% 12.4% 2243 2340 290 224 2163 2102 252 262 208 189 185 225 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Segmental Revenue Cash Flow from Operations (Net) Capex Spent 1396 290 257 1259 1
Slide 28: Summary Statement of Standalone Profit and Loss
Summary Statement of Standalone Profit and Loss Particulars (in INR Cr.) FY26 FY25 FY24 FY23 FY22 Revenue from Operations 2319.1 2079.2 2,132.8 2,217.1 2,184.0 Other Income 21.3 22.4 30.1 25.6 32.0 Total Revenue 2340.3 2101.6 2,162.9 2,242.7 2,216.1 Cost of Materials Consumed 1501.6 1358.3 1,435.1 1
Slide 29: Summary Statement of Standalone Balance Sheet
Summary Statement of Standalone Balance Sheet Particulars (in INR Cr.) Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Particulars (in INR Cr.) Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY (i) Property, plant and equipment 1165.1 1,158.0 921.1 750.5 559.5 (i) Equity
Slide 30: Summary Statement of Standalone Cashflow
Summary Statement of Standalone Cashflow Particulars (in INR Cr.) Mar 26 Mar 25 Mar 24 Mar 23 Mar 22 Cash Flow from Operating Activities Profit before Tax 184.4 137.9 182.6 189.5 222.8 Adjustment for Non-Operating Items 85.1 79.8 59.8 44.4 33.1 Operating Profit before Working Capital Changes 269.5 2
Slide 31: Way Forward
Way Forward Backward Integration for Margin Product Diversification Beyond Scaling Through a Strategic Land Export Contribution to Rise and Supply Chain Resilience Ibuprofen Purchase The non-Ibuprofen share in the pharmaceuticals segment has The company adopts a strategic The company has purchased 1
Slide 32: Thank You
COMPANY : INVESTOR RELATIONS ADVISORS : MUFG Intime India Private Limited A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services IOL Chemicals and Pharmaceuticals Ltd. CIN : L24116PB1986PLC007030 Ms. Prachi Ambre Ms. Irfan Raeen Prachi.ambre@in.mpms.mufg.com irfan.raeen@in.mp
IOL Chemicals and Pharmaceuticals — Q1 FY27 Earnings Presentation on 6ix